Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
Blood|November 10, 1998
Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working PartyE Carreras, H Bertz, W Arcese, et al.
Leukemia|October 7, 2006
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosisN C Gutiérrez, M V Castellanos, M L Martín, et al.
Bone Marrow Transplantation|October 12, 1999
Administration of recombinant human granulocyte colony-stimulating factor to normal donors: results of the Spanish National Donor Registry. Spanish Group of Allo-PBTJ de la Rubia, C Martínez, C Solano, et al.
Blood|October 6, 2001
Standardized, unrelated donor cord blood transplantation in adults with hematologic malignanciesG F Sanz, S Saavedra, D Planelles, et al.
Leukemia|January 24, 2017
Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trialL Rosiñol, A Oriol, A I Teruel, et al.
British Journal of Haematology|September 13, 2001
Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignanciesS Brunet, A Urbano-Ispizua, E Ojeda, et al.
Bone Marrow Transplantation|September 26, 2001
Allogeneic transplantation of CD34+-selected cells from peripheral blood in patients with myeloid malignancies in early phase: a case control comparison with unmodified peripheral blood transplantationA Urbano-Ispizua, S Brunet, C Solano, et al.
Leukemia|July 18, 2013
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometryN Puig, M E Sarasquete, A Balanzategui, et al.
Bone Marrow Transplantation|August 24, 2024
Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamideP Asensi Cantó, I Gómez-Seguí, J Montoro, et al.
British Journal of Haematology|June 10, 2000
Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple MyelomaJ J Lahuerta, J Martinez-Lopez, C Grande, et al.
Pageof 9